http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Novocure (NVCR) Appoints Christoph Brackmann as CFO
-
Novocure Appoints Christoph Brackmann as Chief Financial Officer
-
Novocure Reports Third Quarter 2024 Financial Results
-
Novocure (NVCR) Announces FDA Approval of Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer
-
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
-
Novocure to Report Third Quarter 2024 Financial Results
-
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
-
Novocure (NVCR) Announces Planned CEO Transition
-
Novocure Announces Planned CEO Transition
-
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
-
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
-
Novocure Reports Second Quarter 2024 Financial Results
-
Novocure to Report Second Quarter 2024 Financial Results
-
Novocure (NVCR) Reports METIS Phase 3 Trial Met Primary Endpoint
-
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
-
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
-
Novocure (NVCR) Secures $400M Multi-Tranche Non-Dilutive Debt Financing
-
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
-
Novocure Reports First Quarter 2024 Financial Results
-
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
-
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meetin
-
Novocure to Report First Quarter 2024 Financial Results
-
Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary Endpoint
-
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Me
-
Novocure (NVCR) Reports Phase 3 METIS Trial Met Primary Endpoint
-
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung C
-
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
-
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
-
Novocure (NVCR) Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
-
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
-
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
-
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
-
Novocure (NVCR) Appoints Nicolas Leupin as Chief Medical Officer
-
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
-
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
-
Novocure (NVCR) Announces Portfolio Prioritization and Strategic Restructuring Plan, to Reduce Workforce
-
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
-
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
-
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
-
Novocure Reports Third Quarter 2023 Financial Results
-
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
-
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
-
Novocure to Report Third Quarter 2023 Financial Results
-
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
-
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
-
Novocure (NVCR) Reports Publication of Primary Data from Phase 3 LUNAR Trial
-
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
-
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
-
Novocure to Participate in Upcoming Investor Conferences
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVCR
